Eisai Co., Ltd. (ESAIY) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Eisai Co., Ltd. (ESAIY) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 55/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 17 mar 2026Eisai Co., Ltd. (ESAIY) Resumen de Asistencia Médica y Tuberías
Eisai Co., Ltd., a Japanese pharmaceutical company, specializes in oncology and neurology drugs, holding a significant position in Alzheimer's disease treatment with Aricept and expanding its oncology portfolio with Lenvima, while navigating a competitive landscape and strategic collaborations.
Tesis de Inversión
Eisai Co., Ltd. presents a mixed investment thesis. The company's established presence in the Alzheimer's disease market with Aricept and its growing oncology portfolio with Lenvima provide a stable revenue base. The company's profit margin stands at 5.3% with a gross margin of 77.8%. Upcoming data from its collaboration with Bristol Myers Squibb on farletuzumab ecteribulin antibody drug conjugate could serve as a catalyst. However, the company faces competition from generic drug manufacturers and potential regulatory challenges. The stock's beta of -0.19 suggests low volatility relative to the market. Investors should monitor the success of its pipeline products and the impact of generic competition on Aricept sales.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Eisai Co., Ltd. has a market capitalization of $8.54 billion, reflecting its substantial presence in the pharmaceutical industry.
- The company's P/E ratio is 32.08, indicating the price investors are willing to pay for each dollar of earnings.
- Eisai's gross margin of 77.8% demonstrates efficient cost management in its manufacturing and sales processes.
- The company offers a dividend yield of 3.29%, providing a steady income stream for investors.
- Eisai's strategic collaboration with Bristol Myers Squibb enhances its oncology pipeline and potential for future growth.
Competidores y Pares
Fortalezas
- Strong presence in Alzheimer's disease treatment with Aricept.
- Growing oncology portfolio with Lenvima.
- Strategic collaboration with Bristol Myers Squibb.
- Established global presence and distribution network.
Debilidades
- Reliance on a few key products for revenue.
- Exposure to generic competition.
- High R&D costs.
- Dependence on regulatory approvals.
Catalizadores
- Ongoing: Continued clinical trial progress for Lenvima in new cancer indications.
- Upcoming: Data releases from the collaboration with Bristol Myers Squibb on farletuzumab ecteribulin antibody drug conjugate.
- Ongoing: Expansion of Eisai's presence in emerging markets, such as China and India.
Riesgos
- Ongoing: Generic erosion of Aricept sales due to patent expiration.
- Potential: Regulatory challenges and delays in drug approvals.
- Potential: Increased competition from other pharmaceutical companies.
- Potential: Economic downturns affecting healthcare spending.
- Ongoing: Currency fluctuations impacting the value of ADRs.
Oportunidades de crecimiento
- Expansion of Oncology Portfolio: Eisai's collaboration with Bristol Myers Squibb on farletuzumab ecteribulin antibody drug conjugate represents a significant growth opportunity in the oncology market. The global oncology market is projected to reach $286.6 billion by 2030. Successful development and commercialization of this drug could significantly boost Eisai's revenue and market share. The ongoing clinical trials and regulatory approvals will determine the timeline for this growth driver.
- Alzheimer's Disease Treatment Advancements: Eisai's continued research and development in Alzheimer's disease treatments offer substantial growth potential. The aging global population is driving increased demand for effective Alzheimer's therapies. Eisai's Aricept has been a cornerstone in this area, and new advancements could solidify its leadership. The timeline depends on clinical trial outcomes and regulatory approvals, with potential for significant impact within the next 3-5 years.
- Geographic Expansion into Emerging Markets: Eisai has the opportunity to expand its presence in emerging markets, such as China and India, where healthcare spending is rapidly increasing. These markets offer significant growth potential for Eisai's existing product portfolio and pipeline drugs. The timeline for this expansion depends on regulatory approvals and market entry strategies, with potential for steady growth over the next 5-10 years.
- Strategic Acquisitions and Partnerships: Eisai can pursue strategic acquisitions and partnerships to expand its product portfolio and access new technologies. This approach can accelerate growth and diversify the company's revenue streams. The timing and impact of these opportunities are dependent on market conditions and available targets, with potential for transformative deals in the coming years.
- Development of Novel Therapies for Neurological Disorders: Eisai's focus on neurology provides a platform for developing novel therapies for other neurological disorders beyond Alzheimer's disease. The market for neurological disorder treatments is growing, driven by increasing prevalence and unmet medical needs. Successful development and commercialization of new therapies could significantly contribute to Eisai's long-term growth. The timeline depends on research and development progress and regulatory approvals.
Oportunidades
- Expansion into emerging markets.
- Development of novel therapies for neurological disorders.
- Strategic acquisitions and partnerships.
- Advancements in Alzheimer's disease treatment.
Amenazas
- Generic erosion of key products.
- Increased competition from other pharmaceutical companies.
- Stringent regulatory requirements.
- Economic downturns affecting healthcare spending.
Ventajas competitivas
- Patented pharmaceutical products provide market exclusivity.
- Strong brand recognition in specific therapeutic areas.
- Established distribution network and sales force.
- Strategic collaborations with other pharmaceutical companies.
Acerca de ESAIY
Eisai Co., Ltd., established in 1941 and headquartered in Tokyo, Japan, is a global pharmaceutical company committed to innovative solutions for health and well-being. Originally named Nihon Eisai Co., Ltd., the company adopted its current name in 1955. Eisai focuses on research and development, manufacturing, sales, and import/export of pharmaceutical products. The company's diverse portfolio includes treatments for various therapeutic areas, including oncology, neurology, and gastrointestinal disorders. Key products include Aricept, a leading treatment for Alzheimer's disease, and Lenvima, an anticancer agent used in the treatment of thyroid cancer and hepatocellular carcinoma. Eisai also offers Dayvigo for insomnia, Halaven for breast cancer, and Fycompa for epilepsy. The company has a strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate, enhancing its oncology pipeline. Eisai's commitment to addressing unmet medical needs and improving patient outcomes has solidified its position as a key player in the global pharmaceutical industry.
Qué hacen
- Researches and develops pharmaceutical products.
- Manufactures pharmaceutical drugs.
- Sells and markets pharmaceutical products globally.
- Imports and exports pharmaceutical products.
- Focuses on treatments for oncology, neurology, and gastrointestinal disorders.
- Collaborates with other pharmaceutical companies for drug development and commercialization.
Modelo de Negocio
- Develops and patents innovative pharmaceutical products.
- Generates revenue through the sale of prescription drugs.
- Partners with other companies for co-development and commercialization.
- Invests in research and development to create new therapies.
Contexto de la Industria
Eisai Co., Ltd. operates within the competitive pharmaceutical industry, facing challenges from both established players and generic drug manufacturers. The industry is characterized by high R&D costs, stringent regulatory requirements, and patent expirations. Eisai's focus on specialty drugs, particularly in oncology and neurology, positions it in high-growth areas. The global pharmaceutical market is expected to continue expanding, driven by an aging population and increasing demand for innovative treatments. Eisai's strategic collaborations and pipeline development are crucial for maintaining its competitive edge in this dynamic landscape.
Clientes Clave
- Patients requiring treatments for various diseases.
- Hospitals and clinics.
- Pharmacies and drug distributors.
- Healthcare providers.
Finanzas
Gráfico e información
Precio de la acción de Eisai Co., Ltd. (ESAIY): Price data unavailable
Últimas noticias
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ESAIY.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para ESAIY.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de ESAIY en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Haruo Naito
CEO
Haruo Naito has served as the CEO of Eisai Co., Ltd. He has been with Eisai for many years, holding various leadership positions within the company. His career has been dedicated to the pharmaceutical industry, with a focus on research and development, strategic planning, and global market expansion. He is responsible for managing 11067 employees. Naito's leadership is focused on innovation and addressing unmet medical needs.
Historial: Under Haruo Naito's leadership, Eisai has focused on expanding its oncology portfolio and strengthening its position in the Alzheimer's disease market. Key milestones include the strategic collaboration with Bristol Myers Squibb and the continued development of innovative therapies. He has overseen the growth of Lenvima and the continued success of Aricept. Naito has emphasized a patient-centric approach and a commitment to addressing global health challenges.
Información de ADR de Eisai Co., Ltd. No patrocinado
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. ESAIY is an ADR that allows U.S. investors to invest in Eisai Co., Ltd. without directly purchasing shares on the Tokyo Stock Exchange. It simplifies trading and reduces complexities associated with international investing.
- Ticker del mercado local: Tokyo Stock Exchange, Japan
- Nivel de ADR: 1
- Ratio de ADR: 1:1
- Ticker del mercado local: ESAI
Información del mercado OTC de ESAIY
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited or no financial disclosure requirements, and they may not meet the minimum listing standards of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the lack of transparency and regulatory oversight.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases the risk of investing in ESAIY on the OTC market.
- Low trading volume and wide bid-ask spreads can lead to price volatility and difficulty in executing trades.
- Lack of regulatory oversight increases the potential for fraud or mismanagement.
- The company may not meet the listing standards of major exchanges, indicating potential financial or operational challenges.
- The OTC Other tier carries a higher risk of delisting or trading suspension.
- Verify the company's registration and legal status.
- Obtain and review any available financial reports or disclosures.
- Assess the company's management team and their track record.
- Research the company's products, services, and market position.
- Evaluate the company's competitive landscape and potential risks.
- Consult with a financial advisor or legal professional.
- Understand the risks associated with investing in OTC securities.
- Eisai Co., Ltd. is a well-established pharmaceutical company with a global presence.
- The company has a diverse portfolio of pharmaceutical products and a history of innovation.
- Eisai has strategic collaborations with other reputable pharmaceutical companies.
- The company is listed on the Tokyo Stock Exchange (ESAI), providing some level of regulatory oversight.
- Eisai has a dedicated investor relations team and provides some information to investors.
Lo Que los Inversores Preguntan Sobre Eisai Co., Ltd. (ESAIY)
¿Cuáles son los factores clave para evaluar ESAIY?
Eisai Co., Ltd. (ESAIY) actualmente tiene una puntuación IA de 55/100, indicando puntuación moderada. Fortaleza clave: Strong presence in Alzheimer's disease treatment with Aricept.. Riesgo principal a monitorear: Ongoing: Generic erosion of Aricept sales due to patent expiration.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de ESAIY?
ESAIY actualmente puntúa 55/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de ESAIY?
Los precios de ESAIY se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre ESAIY?
La cobertura de analistas para ESAIY incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en ESAIY?
Las categorías de riesgo para ESAIY incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Generic erosion of Aricept sales due to patent expiration.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de ESAIY?
La relación P/E para ESAIY compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está ESAIY sobrevalorada o infravalorada?
Determinar si Eisai Co., Ltd. (ESAIY) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de ESAIY?
Eisai Co., Ltd. (ESAIY) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- Investment decisions should be based on individual research and risk assessment.